DocSym
β
Searchsearch
Search
(H17.0) Adherent leukoma
More details coming soon
69 098 in individuals diagnosis adherent leukoma confirmed
Diagnosis adherent leukoma is diagnosed Men are 16.55% more likely than Women
40 268
Men receive the diagnosis adherent leukoma
0 (less than 0.1%)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
28 830
Women receive the diagnosis adherent leukoma
0 (less than 0.1%)Died from this diagnosis.
Risk Group for the Disease adherent leukoma - Men aged 55-59 and Women aged 75-79
In Men diagnosis is most often set at age 0-89
Less common in men the disease occurs at Age 90-95+Less common in women the disease occurs at Age 0-1, 25-29
In Women diagnosis is most often set at age 0-24, 30-95+
Disease Features adherent leukoma
Absence or low individual and public risk
Adherent leukoma - what does this mean
Adherent leukoma is a rare form of eye disease caused by a mutation of the pax6 gene. it is characterized by the formation of a white, opaque membrane over the surface of the cornea that can block vision. the membrane is composed of abnormal, thickened layers of cells that adhere to the surface of the cornea, resulting in decreased vision.
What happens during the disease - adherent leukoma
Adherent leukoma is an inflammatory disorder of the conjunctiva that is caused by an immune reaction to a foreign body or an infection. it is characterized by the formation of thickened white lesions on the conjunctiva, which are composed of inflammatory cells and fibroblasts. these lesions can become adherent to the cornea, leading to scarring, decreased vision and, in some cases, blindness. the underlying cause of the disorder is not known, but it is thought to be related to an immune response to a foreign body or infection. treatment typically involves topical steroids, antibiotics, and, in some cases, surgical removal of the affected tissue.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Physical examination of the eye
- Slit-lamp examination
- Ultrasound biomicroscopy
- Gonioscopy
- Optical coherence tomography (OCT)
- Indirect ophthalmoscopy
- Fluorescein angiography
- Tear film break-up time (TBUT) test
- Schirmer's test
- Corneal topography
Treatment and Medical Assistance
Main goal: Treat Adherent Leukoma
- Prescribe antibiotics
- Perform surgery to remove the leukoma
- Administer steroid injections
- Prescribe anti-inflammatory medications
- Apply topical medications
- Monitor patient for signs of infection
- Provide patient with lifestyle advice
- Provide patient with emotional support
9 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Adherent leukoma - Prevention
Adherent leukoma can be prevented by avoiding direct contact with an infected person, practicing good hygiene, and avoiding contact with contaminated objects. additionally, immunization is available for some forms of leukoma, and should be considered for those at risk.